GO M400
Alternative Names: GO-M400Latest Information Update: 15 Jan 2025
Price :
$50 *
At a glance
- Originator GO Therapeutics; Xyphos
- Developer GO Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Solid tumours